Drug Discovery Chemistry is a dynamic conference for medicinal, biophysical, and computational chemists working across pharma, biotech, and academia. Focused on discovery and optimization challenges of small-molecule and macrocyclic drug candidates, the 2026 event features new sessions spanning AI- and ML-driven design, fragment- and structure-based discovery, molecular glues and degraders, DNA-encoded libraries, and emerging biophysical tools. Attendees can tailor their experience by exploring concurrent tracks covering today’s most innovative approaches to drug discovery.
As in the past, speaker participation by industry is once again very strong, with presentations from AbbVie, Amgen, Astex Pharmaceuticals, AstraZeneca, Bayer, Eli Lilly, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, and numerous emerging biotechs. Final agendas have recently been announced – Secure your spot with Early Rates by January 23.